Dr Reddy's Laboratories Ltd
Ticker: DRREDDY
Decent
48/100
☆ Add to Watchlist
Investing Reference
Price
1232.40
Market Cap
102585.45
Debt/Equity
0.1378
ROE %
18.189
PB
3.0237
Promoter %
26.637
Pledge %
0.000
1Y Rev Growth %
16.745
5Y Rev Growth %
13.163
NP Margin %
16.749
NP Margin 5Y Avg %
14.695
Trading Reference
1M Return %
-5.441
6M Return %
6.711
1Y Return %
-6.801
% Away 52W High
14.078
% Away 52W Low
20.824
Daily Volume
2150067
Investment Verdict
Hold
Score 68/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 30/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Dr Reddy's Laboratories Ltd is likely to experience a moderate upside in the medium-term, with potential resistance around the 52-week high. If it breaks through this level, it could see further gains. However, there is also a risk of downside if it falls below key support levels, indicating potential volatility.
Upside Probability: 15% | Downside Probability: 10%
Probability estimates are technical-context statements, not investment advice.
More Options
D
Dixon Technologies (India) Ltd
Dixon Technologies shows potential for growth in a favorable sector, but valuation concerns and execution risks should be monitored closely.
View details
T
Tata Consumer Products Ltd
Tata Consumer Products Ltd shows decent potential with strong growth prospects, but faces challenges in valuation and execution risks.
View details
P
Polycab India Ltd
Polycab India Ltd shows a decent investment potential with strong fundamentals, but investors should be cautious of valuation and execution risks.
View details
S
Shree Cement Ltd
Shree Cement Ltd shows decent fundamentals with growth potential, but faces challenges in profitability and valuation metrics.
View details
M
Mankind Pharma Ltd
Mankind Pharma Ltd shows potential for growth but faces challenges in profitability and valuation metrics.
View details
H
Hero MotoCorp Ltd
Hero MotoCorp has a decent standing in the market, but faces challenges in growth consistency and valuation metrics. The transition to electric vehicles and competition will be critical for future performance.
View details
J
Jindal Steel Ltd
Jindal Steel Ltd shows decent potential with consistent growth, but faces challenges in profitability and valuation metrics.
View details
Z
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd shows potential for growth, but faces challenges in profitability and market competition.
View details
W
Waaree Energies Ltd
Waaree Energies Ltd shows potential in the renewable energy sector, but faces challenges in profitability and execution risks.
View details
U
Union Bank of India Ltd
Union Bank of India shows moderate potential with some growth prospects, but faces challenges in profitability and execution risks.
View details
C
Canara Bank Ltd
Canara Bank shows potential for moderate growth but faces challenges in profitability and execution risks.
View details
I
IDBI Bank Ltd
IDBI Bank Ltd presents a risky investment opportunity with moderate growth and profitability concerns.
View details
A
Adani Energy Solutions Ltd
Adani Energy Solutions Ltd shows potential in a growing sector, but faces significant challenges that could impact its performance.
View details
H
Havells India Ltd
Havells India Ltd shows a decent investment opportunity with strong growth potential, but investors should be cautious of valuation and execution risks.
View details
R
REC Limited
REC Limited shows potential for growth in a vital sector, but investors should be cautious of execution risks and governance issues.
View details
S
Swiggy Ltd
Swiggy Ltd shows potential for growth but faces significant challenges in profitability and competition. Caution is advised.
View details
Business Overview
Dr Reddy's Laboratories Ltd is a leading Indian pharmaceutical company dedicated to providing affordable and innovative healthcare solutions. Catering to patients, healthcare professionals, and partners, the company focuses on developing a wide range of generic medicines, active pharmaceutical ingredients, and proprietary products. With a strong commitment to quality and sustainability, Dr Reddy's plays a crucial role in enhancing global health outcomes. Its robust pipeline and strategic collaborations position it as a key player in the pharmaceutical industry.
- Established leader in the Indian pharmaceutical sector
- Wide range of generic and proprietary medicines
- Strong commitment to quality and innovation
- Focus on affordable healthcare solutions
- Strategic global partnerships and collaborations
Investment Thesis
Dr Reddy's Laboratories presents a compelling investment opportunity due to its strong promoter credibility, robust growth in digital services, and attractive valuation compared to peers. The company's commitment to innovation and expansion in international markets further enhances its growth prospects.
- Strong promoter group with a proven track record in the pharmaceutical industry.
- Significant growth potential in digital services, catering to evolving healthcare needs.
- Attractive valuation metrics compared to industry peers, offering a favorable entry point.
- Diverse product portfolio and expanding global footprint bolster revenue streams.
- Focus on R&D and strategic partnerships positions the company for long-term success.
Opportunity vs Risk
Opportunities
- Strong pipeline of new drugs
- Expansion in international markets
- Growing demand for generics
- Strategic partnerships with global firms
Risks ⚠️
- Regulatory challenges in key markets
- Currency fluctuations impacting profits
- Intense competition in generics
- Potential supply chain disruptions
Peer Perspective
Dr Reddy's Laboratories Ltd trades at a discount to peers like Sun Pharma and Cipla, reflecting concerns over margin stability; a sustained improvement in operational efficiency could trigger a rerating in its valuation.
Future Outlook
Dr Reddy's Laboratories is well-positioned for growth with its robust pipeline and expanding global presence, provided the company maintains strong execution and cost control measures to navigate market challenges.
AI FAQs for Retail Users
- Q: What does Dr Reddy's Laboratories do?A: Dr Reddy's Laboratories is a global pharmaceutical company that develops and manufactures a wide range of medications.
- Q: Is Dr Reddy's a good investment?A: Investment decisions should be based on individual research and financial goals; consult a financial advisor for personalized advice.
- Q: What are the main products of Dr Reddy's?A: The company offers generic drugs, active pharmaceutical ingredients, and proprietary medicines across various therapeutic areas.
- Q: How can I buy shares of Dr Reddy's?A: You can buy shares through a stockbroker or an online trading platform that offers access to Indian stock markets.
- Q: What are the risks of investing in Dr Reddy's?A: Risks include market volatility, regulatory changes, and competition in the pharmaceutical industry.
📊 Stock Investment Checklist (100 Points)
Dr Reddy's Laboratories Ltd • Updated: 2025-09-16 20:32:30
-
10BusinessHighPharmaceutical sector is essential and growing, but faces regulatory challenges.
-
10GrowthHighConsistent revenue growth, but profit margins are under pressure.
-
10ProfitabilityHighROE and ROCE are decent, but OCF has shown volatility.
-
10ValuationHighValuation metrics are in line with peers, but growth expectations are tempered.
-
8BalanceHighModerate debt levels, but liquidity is adequate.
-
7GovernanceHighPromoter holding is strong, but some concerns over pledging.
-
8DriversHighStrong product pipeline, but execution risks remain.
-
5TechnicalsGoodMarket sentiment is mixed, with low liquidity.
Final Score & Verdict
Score 48 / 100
• Decent
Dr Reddy's Laboratories shows potential with a solid business model and growth prospects, but faces challenges in profitability and market sentiment.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 80/100
- Governance: 85/100
- Market Confidence: 78/100